Evidence map›Paper›PMID 35986358›Full record

Trial reportJournal of translational medicine2022

A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease.

Yvelise Ferro, Roberta Pujia, Elisa Mazza, Lidia Lascala, Oscar Lodari, Samantha Maurotti, Arturo Pujia, Tiziana Montalcini

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Effect of Citrus bergamia Supplementation on Body Composition in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Wild Artichoke (Molecules (Basel, Switzerland) · 2023
    Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yvelise Ferro *Department of Medical and Surgical Science, University Magna Græcia, 88100, Catanzaro, Italy.
Roberta Pujia *Department of Medical and Surgical Science, University Magna Græcia, 88100, Catanzaro, Italy.
Elisa MazzaDepartment of Medical and Surgical Science, University Magna Græcia, 88100, Catanzaro, Italy.
Lidia LascalaDepartment of Clinical and Experimental Medicine, University Magna Greæcia, Catanzaro, Italy.
Oscar LodariDepartment of Clinical and Experimental Medicine, University Magna Greæcia, Catanzaro, Italy.
Samantha MaurottiDepartment of Clinical and Experimental Medicine, University Magna Greæcia, Catanzaro, Italy.
Arturo PujiaDepartment of Medical and Surgical Science, University Magna Græcia, 88100, Catanzaro, Italy.
Tiziana MontalciniDepartment of Clinical and Experimental Medicine, University Magna Greæcia, Catanzaro, Italy. tmontalcini@unicz.it.ORCID 0000-0001-7048-5830
Magna Graecia University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, there is no approved medication for non-alcoholic fatty liver disease management. Pre-clinical and clinical studies showed that several bioactive molecules in plants or foods (i.e., curcumin complex, bergamot polyphenol fraction, artichoke leaf extract, black seed oil, concentrate fish oil, picroliv root, glutathione, S-adenosyl-L-methionine and other natural ingredients) have been associated with improved fatty liver disease. Starting from these evidences, our purpose was to evaluate the effects of a novel combination of abovementioned nutraceuticals as a treatment for adults with fatty liver disease.

methodsA total of 140 participants with liver steatosis were enrolled in a randomized, double-blind, placebo controlled clinical trial. The intervention group received six softgel capsules daily of a nutraceutical (namely Livogen Plus®) containing a combination of natural bioactive components for 12 weeks. The control group received six softgel capsules daily of a placebo containing maltodextrin for 12 weeks. The primary outcome measure was the change in liver fat content (CAP score). CAP score, by transient elastography, serum glucose, lipids, transaminases, and cytokines were measured at baseline and after intervention.

resultsAfter adjustment for confounding variables (i.e., CAP score and triglyceride at baseline, and changes of serum γGT, and vegetable and animal proteins, cholesterol intake at the follow-up), we found a greater CAP score reduction in the nutraceutical group rather than placebo (- 34 ± 5 dB/m vs. - 20 ± 5 dB/m, respectively; p = 0.045). The CAP score reduction (%) was even greater in those with aged 60 or less, low baseline HDL-C, AST reduction as well as in men.

conclusionOur results showed that a new combination of bioactive molecules as nutraceutical was safe and effective in reducing liver fat content over 12 weeks in individuals with hepatic steatosis. Trial registration ISRCTN, ISRCTN70887063. Registered 03 August 2021-retrospectively registered, https://doi.org/10.1186/ISRCTN70887063.

Indexed as

Elasticity Imaging TechniquesNon-alcoholic Fatty Liver DiseaseDietary SupplementsDouble-Blind MethodHumansLiverBioactive componentsFatty liver diseaseHepatic steatosisNutraceutical

Identifiers

PMID35986358
PMCPMC9392294
OpenAlexW4292348690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.